GoldenGolden
Translate Bio

Translate Bio

A clinical-stage mRNA therapeutics company developing medicines to treat diseases caused by protein or gene dysfunction and vaccines against infectious disease pathogens

Translate Bio is a clinical-stage mRNA therapeutics company developing medicines to treat diseases caused by protein or gene dysfunction and vaccines against infectious disease pathogens. Translate Bio is primarily focused on pulmonary diseases caused by insufficient protein production or diseases where a treatment that causes a reduction of certain proteins can modify the disease. The company’s lead program is a treatment for cystic fibrosis (CF) which as of April, 2020 was in a phase 1/2 clinical trial.

Translate Bio has a proprietary mRNA therapeutic platform (MRT) used to generate mRNA that encodes functional proteins. The mRNA is encapsulated in lipid nanoparticles for delivery into target cells where it will be translated into protein. The MRT platform enables the delivery of mRNA that carries instructions to produce intracellular, transmembrane and secreted proteins. mRNA sequences are optimized for efficient protein production. Optimized tissue-specific delivery vehicles are used to deliver to the targeted cell type.

Translate Bio began a collaboration and exclusive licensing agreement with Sanofi Pasteur in 2018 to develop mRNA vaccines for up to five infectious disease pathogens.

Translate Bio is producing mRNA constructs and will use its RNA platform to discover, design and manufacture SARS-CoV-2 vaccine candidates to treat COVID-19. The company will partner with Sanofi Pasteur who will provide expertise and support to further advance vaccine candidates. Translate Bio can produce 100 gram single-batch production and is building a dedicated manufacturing space to accommodate around two 250 gram batches per month.

Timeline

May 3, 2019
Translate Bio raises a $47,500,000 venture round.
December 1, 2017
Translate Bio raises a $42,000,000 series C round from Baupost Group, Fidelity Management & Research Company and Omega Funds.
January 10, 2017
Translate Bio raises a $51,000,000 series C round from Atlas Venture, Baupost Group, Fidelity Management & Research Company, MRL Ventures Fund, Omega Funds and Sr One.
July 30, 2015
Translate Bio raises a $63,800,000 series B round from Baupost Group, Fidelity Management & Research Company, Leerink Partners, M Ventures, MRL Ventures Fund, Monsanto Growth Ventures, Omega Funds, Partners Innovation Fund, Pfizer Venture Investments, Rock Springs Capital and Sr One.
January 18, 2012
Translate Bio raises a $20,700,000 series A round from Atlas Venture.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
May 27, 2021
BioSpace
Sanofi and GSK started enrollment in their Phase 3 clinical study to assess the safety, efficacy, and immunogenicity of their adjuvanted recombinant-protein COVID-19 vaccine candidate.
BioSpace
May 18, 2021
BioSpace
- Positive results suggest potential for an mRNA-based therapeutic to correct ciliary function in patients with PCD due to DNAI1 mutations - - Company expects to advance a lead PCD candidate into IND-enabling studies in 2H 2021
BioSpace
May 17, 2021
BioSpace
Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adultage groups in Phase 2 trial
BioSpace
April 19, 2021
BioSpace
- - Seasoned healthcare executive, Brendan Smith, appointed as Chief Financial Officer, bringing strategic operations and financial leadership -- -- Appointments enhance capabilities across pulmonary programs, manufacturing and financial operations with a goal of advancing platform, preclinical and clinical milestones --
BioSpace
April 19, 2021
BioSpace
-- Multiple antigen constructs, including the construct used in MRT5500, induced potent neutralizing antibodies against SARS-CoV-2 in preclinical studies in multiple species -- -- Efficacy demonstrated in Syrian Golden Hamster challenge model under single and two-dose vaccination regimens of MRT5500 -- -- MRT5500 developed under a collaboration agreement with Sanofi Pasteur; Phase 1/2 clinical trial underway with clinical data anticipated in the third quarter of 2021 --
Nick Paul
March 18, 2021
FierceBiotech
A small clinical trial has found no pattern of improvements in lung function in cystic fibrosis patients who received Translate Bio's mRNA prospect MRT5005. The setback, which sent the biotech's stock down 24%, was softened somewhat by evidence that repeated inhaled doses of mRNA are safe.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.